Liraglutide (Victoza / Saxenda)
The daily GLP-1 receptor agonist that preceded semaglutide — still widely prescribed in India for type 2 diabetes (Victoza) and weight management (Saxenda). Less potent than semaglutide but with strong cardiovascular outcome data and established tolerability.
What Is Liraglutide?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk — the same company behind semaglutide. It was the first weekly-class GLP-1 agonist to gain widespread clinical use, predating semaglutide by several years. Unlike semaglutide's 7-day half-life enabling weekly injection, liraglutide has a half-life of approximately 13 hours, requiring daily subcutaneous injection.
Liraglutide is marketed under two brand names for different indications:
- Victoza: 0.6mg, 1.2mg, and 1.8mg doses — approved for type 2 diabetes management
- Saxenda: 3mg dose (higher) — approved for chronic weight management in adults and adolescents
Mechanism of Action
Liraglutide activates GLP-1 receptors through the same mechanisms as semaglutide:
- Appetite suppression via hypothalamic GLP-1 receptors
- Slowed gastric emptying → prolonged satiety after meals
- Glucose-dependent insulin secretion from pancreatic beta cells
- Suppression of glucagon from alpha cells → reduced hepatic glucose output
The mechanism is identical to semaglutide; the practical difference is half-life, dosing frequency, and maximum achievable plasma concentration. Semaglutide reaches higher sustained plasma levels at therapeutic doses, producing greater appetite suppression and weight loss. The LEADER trial (PubMed, 2016) established liraglutide's cardiovascular benefits.
Victoza vs Saxenda
| Feature | Victoza | Saxenda |
|---|---|---|
| Active ingredient | Liraglutide | Liraglutide |
| Approved indication | Type 2 diabetes | Chronic weight management |
| Maximum dose | 1.8mg/day | 3.0mg/day |
| Weight loss data | 3–4kg average | 5–7% body weight |
| India availability | Widely available | Limited availability |
LEADER Trial — Cardiovascular Evidence
The LEADER trial enrolled 9,340 adults with T2D and high cardiovascular risk over 3.8 years. Liraglutide 1.8mg/day reduced the composite MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 13% versus placebo. Cardiovascular death was specifically reduced by 22%.
This was among the first trials to establish that GLP-1 agonists have cardiovascular benefits beyond glycemic control — paving the way for the more impressive 20–26% MACE reductions seen with semaglutide. The LEADER data established liraglutide's cardiovascular credentials that inform India prescribing guidelines.
Weight Loss: Liraglutide vs Semaglutide
The evidence clearly favours semaglutide for weight loss:
| Drug | Daily/Weekly | Average Weight Loss | % Losing ≥10% |
|---|---|---|---|
| Liraglutide 1.8mg (Victoza) | Daily | 3–4kg (~3–4%) | ~15% |
| Liraglutide 3mg (Saxenda) | Daily | 5–6% | ~33% |
| Semaglutide 1mg (Ozempic) | Weekly | ~6% | ~40% |
| Semaglutide 2.4mg (Wegovy) | Weekly | 15–17% | ~70% |
Why Patients Transition from Liraglutide to Semaglutide
The transition happens for several practical reasons:
- Greater efficacy: Semaglutide 2.4mg produces 2–3x more weight loss
- Convenience: Once-weekly vs daily injection — significantly improves adherence
- Comparable tolerability: Both have similar GI side effect profiles
- Semaglutide generics: From March 2026, semaglutide generics in India are cheaper than branded Victoza for equivalent or greater efficacy
Liraglutide retains a role for patients who specifically prefer daily dosing flexibility, those where semaglutide's longer half-life is a concern, or where liraglutide has been well-established in a patient's regimen with good tolerability.
Injection Technique and Storage
Liraglutide follows the same subcutaneous injection technique as semaglutide — abdomen, outer thigh, or upper arm, rotating sites daily. The pen uses 32G×4mm needles (sold separately). Storage: refrigerate at 2–8°C until first use; room temperature below 30°C for up to 30 days after opening.
With India's heat, never leave liraglutide pens at room temperature for more than 30 days. In summer months (April–June), use an insulated pouch if carrying the pen outside air-conditioned spaces. Degraded liraglutide (from heat exposure) appears slightly yellowed — discard if discolored.
Biomarker Monitoring on Liraglutide
- HbA1c: Expect 0.8–1.5% reduction at 1.8mg; check every 3 months
- Fasting glucose: Should improve within 4–8 weeks
- Lipids: Modest improvement — LDL, triglycerides
- Weight and waist: Track monthly; 3–4kg loss expected over 6 months
- Amylase/lipase: Baseline then if symptoms arise
Frequently Asked Questions
What is the difference between liraglutide and semaglutide?
Both are GLP-1 receptor agonists but differ critically in half-life. Liraglutide requires daily injection (13-hour half-life); semaglutide requires only once-weekly injection (7-day half-life). Semaglutide is more potent — producing 12–17% weight loss vs 5–7% for liraglutide at respective maximum doses. Most new patients are started on semaglutide where available.
Is Victoza available in India?
Yes. Victoza (liraglutide 1.2mg and 1.8mg) is available in India at major pharmacy chains and hospital pharmacies. It is a Schedule H prescription drug. Saxenda (3mg for weight management) has more limited availability in India compared to Victoza.
Can liraglutide cause weight loss?
Yes, but moderately. At Victoza doses (1.8mg/day), average weight loss is 3–4kg. At the Saxenda weight management dose (3mg/day), trials showed 5–7% body weight loss — clinically meaningful but significantly less than semaglutide. If weight loss is the primary goal, semaglutide or tirzepatide are more effective options.
How does liraglutide compare to Ozempic?
Ozempic (semaglutide) is superior in weight loss (5–12% vs 3–7%), dosing convenience (once weekly vs daily), and likely magnitude of cardiovascular benefit. Liraglutide has strong LEADER trial data (13% MACE reduction) and established tolerability. For new patients in India, semaglutide generics are now comparable in price and superior in efficacy.